Bendamustine, vincristine, prednisolone in relapsed and refractory low grade non-Hodgkin's lymphoma;Bendamustin, vincristin, prednisolon (BOP) in der therapie von fortgeschrittenen niedrig malignen non-Hodgkin-lymphomen

Deutsche Medizinische Wochenschrift

Volumn 126, Issue 8, 2001, Pages 198-202

  Kath, R ^a   Blumenstengel, K ^a   Fricke, H J ^a   Peters, H D ^b   Hoffken K ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; MALIGNANT TRANSFORMATION; NONHODGKIN LYMPHOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; FEMALE; HUMANS; LYMPHOMA, LOW-GRADE; MALE; MIDDLE AGED; SALVAGE THERAPY; TREATMENT OUTCOME; VINCRISTINE;

EID: 0035936927     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-11316     Document Type: Article

References (33)

1. Vergleichsuntersuchungen zwischen cytostasan und cyclophosphamid bei der chronischen lymphadenose, dem plasmozytom, der lymphogranulomatose und dem bronchialkarzinom
2. Erste klinische erfahrungen mit einem neuen zytostatikum
3. Klinischer erfahrungsbericht über die anwendung des neuen zytostatikums 3393
4. Bendamustine versus melphalan in the primary treatment of multiple myeloma (MM). A randomized prospective study
5. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia (CLL)
6. Bendamustine: Effective salvage chemotherapy in pretreated low grade Non-Hodgkin-Lymphomas (L.Gr.NHL)
7. Bendamustine, a low toxic nitrogenmustard derivative with high efficacy in malignant lymphomas
8. Therapieergebnisse und toxische nebenwirkungen der kombination cytostasan, adriamycin und vincristin als »second-line-therapie« beim metastasierten mammakarzinom
9. Phase I-study of weekly bendamustine in patients with solid tumors
10. Bendamustine (B) and mitoxantrone (MITX) in the treatment of low-grade Non-Hodgkin-Lymphoma (NHL)
11. Bendamustine in untreated small cell lung cancer (SCLC): Efficacy and toxicity
12. Zur rezidivtherapie mit bendamustin bei patienten mit Non-Hodgkin-Lymphomen von niedrigem malignitätsgrad und plasmozytomen
13. Relapse therapy with bendamustine in patients with low grade non Hodgkins lymphioma (NHL): Efficacy and toxicity
14. Vorläufige ergebnisse einer zyklisch-alternierenden chemotherapie (CVPP/DBCy) bei fortgeschrittenem Morbus Hodgkin
15. BOP versus COP in advanced low grade Non-Hodgkin's Lymphomas - Results of a randomized multicenter study
16. Bendamustine as salvage treatment in patients with advanced progressive breast cancer: A phase II study
17. Dexa-BId, a bendamustine hydrochloride containing regimen for refractory and relapsed low grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia
18. Bendamustine, methotrexate, mitoxantrone and prednisolone (BMMP) for the treatment of relapsed or refractory high-grade non-Hodgkins lymphoma
19. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia
20. Prevention of immunological complications in bendamustine treatment
21. Response of refractory and relapsed low grade non-Hodgkins lymphoma and chronic lymphocytic leukemia to Dexa-Bid, a bendamustinehydrochlorid containing regimen
22. Response and toxicities of chemotherapy with gemcitabine and bendamustine in advanced ovarian and breast cancer
23. A randomized multicenter study of bendamustine/prednisone versus melphalane/prednisone in the treatment of multiple myeloma
24. Pharmacological and clinical data of bendamustine
25. Chemotherapie des fortgeschrittenen nicht-kleinzelligen und kleinzelligen bronchialkarzinoms mit bendamustin - Eine phase II-studie
26. Therapy of low grade Non-Hodgkin's lymphoma (NHL) with bendamustine and oral etoposide
27. Cytostasan (Bendamustin) in der alternativtherapie maligner Non-Hodgkin-Lymphome
28. Recurrent ENT tumors treated with bendamustine or gemcitabine and radiotherapy
29. Bendamustine/mitoxantrone in the treatment of advanced breast cancer
30. Vergleichende untersuchungen über die zytostatische wirkung des neuen n-lost-derivats »IMET 3393« und endoxan an drei experimentellen mäusetumoren (Ehrlich-Karzionom, Sarkom 180 solid, Leukämie LAJ 1)
31. Repeated administration of short infusions of bendamustine: A phase 1 study in patients with advanced progressive solid tumors
32. Weekly administration of bendamustine: A phase I study in patients with advanced progressive solid tumours